PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus

• Published in: BMC medical genomics Vol. 14; no. 1; p. 267
• Main Authors: Wang, Tao, Song, Jin-Fang, Zhou, Xue-Yan, Li, Cheng-Lin, Yin, Xiao-Xing, Lu, Qian
• Format: Journal Article
• Language: English
• Published: England BioMed Central 12.11.2021; BMC
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Alleles; Beta cells; China; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - genetics; Enzymes; Female; Gene frequency; Gene polymorphism; Genes; Genetic polymorphism; Genotype; Genotype & phenotype; Glucose; Homeostasis; Humans; Hypoglycemic Agents - therapeutic use; Insulin; Insulin resistance; Male; Metabolic syndrome; Nateglinide; Nateglinide - therapeutic use; NOS1AP; Patients; Peroxisome proliferator-activated receptors; Polymerase chain reaction; Polymorphism; Polymorphism, Single Nucleotide; PPAR delta - genetics; PPARD; Restriction fragment length polymorphism; Treatment Outcome; Type 2 diabetes mellitus; China; Beijing China; Type 2 diabetes mellitus; Genetic polymorphism; NOS1AP; Nateglinide; PPARD

Genetic polymorphisms in the PPARD and NOS1AP is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide. This study was designed to investigate a potential association of PPARD rs2016520 (T/C) and NOS1AP rs12742393 (...